Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
  • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D249/12—Oxygen or sulfur atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/32—Alcohol-abuse
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
  • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
  • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
  • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the invention relates to novel 5-hydroxytryptamine (5-HT) receptor agonist compounds, to pharmaceutical compositions comprising these compounds and to the use of the compounds for the treatment of conditions associated with 5-HT action.
• 5-HT 5-hydroxytryptamine
• the 5-HT 1A receptor is a 5-HT receptor subtype consisting of a 421 amino acid protein with a molecular weight of about 42,000 Daltons.
• 5-HT 1A receptors are located presynaptically in the raphe nuclei, where they act as cell body autoreceptors to inhibit the firing rate of 5-HT neurons, and are located postsynaptically in limbic and cortical regions, where they also attenuate firing activity. Recent studies have indicated that 5-HT [A agonists and partial agonists are particularly relevant to the treatment of anxiety and depression.
• 5-HT 1A agonists are azapirones, e.g. Buspirone (disclosed in US 4, 182,763) , Gepirone, Zalospirone, Ipsapirone and Tandospirone.
• Buspirone Dislosed in US 4, 182,763
• Gepirone e.g., Gepirone
• Zalospirone e.g., Ipsapirone
• Tandospirone e.g. Buspirone
• these compounds can cause unpleasant side effects, such as dizziness, fatigue, nausea, nervousness, light-headedness and restlessness.
• the azapirones also suffer from rapid metabolism leading to a very short elimination half-life ( ⁇ 2-3h) , which necessitates a twice daily dosing regime.
• US 4,487,773 discloses phenoxylalkyl substituted-l ,2,4-triazolones having anti-depressant properties (including 3H-l ,2,4-triazole-3-one, 5-[3-[4-(3- chlorophenyl)-l-piperazinyl]propyl]-4-ethyl-2,4-dihydro which is described as an intermediate)
• WO 2004/069794 discloses arylpiperazinyl sulphonamide compounds, and uses thereof for treating diseases including those mediated directly or indirectly by 5- ⁇ T receptors.
• triazolone intermediates are also listed in chemical abstract databases with no associated with reference or uses, for example: 3H-l ,2,4-triazole-3- thione, 2,4-dihydro-5-[2-[4-(2-methoxyphenyl)-l-piperazinyl]ethyl]-4-phenyl (CAS Registry No. RN 418780-84-4) , 3H-l ,2,4-triazole-3-thione, 5-[2-[4- chlorophenyl)-l-piperazinyl]ethyl]-2,4-dihydro-4-phenyl (CAS Registry No. 418785-15-6) and 3H-l ,2,4-triazole-3-thione, 5-[[4-[3-chloro-5-
• each R 1 independently represents halogen, -CF 1 , -NO 2 , Ci_ 6 alkoxy, -NR 6 COR 7 or
• m represents an integer from 1 to 2, such that when m represents 2, said R 1 groups are not both -NR 6 COR 7 or both -NR 6 SO 2 R 7 or both -NO 2 ;
• R 2 represents C ⁇ 6 alkyl, aryl, or C 1 8 cycloalkyl, wherein said aryl may be optionally substituted by one or more (e.g. 1 or 2) R 8 substituents;
• R', R 4 , R 5 , R 6 and R 7 independently represent hydrogen or C, 6 alkyl
• T represents a linker selected from -(CH 2 ) n - and C 3 . 8 cycloalkyl; n represents an integer from O to 4;
• X represents an O or S atom
• Y and Z independently represent a CH or N atom;
• W represents a bond, or a linker selected from -C(R 9 ) (R 10 )- and C 3 . 8 cycloalkyl, wherein R 9 and R 10 independently represent hydrogen, C,. 6 alkyl or aryl; with the proviso that the compound of formula (I) is not:
• the compounds of formula (I) have been found to be 5-HT agonists, for example 5-HT 1 receptors agonists, such as 5-HT 1A , 5-HT,,,, 5-HT, c , 5-HTi D , 5-TH 1E or 5-HT, F agonists, for instance 5-HT, A agonists, that can be used for the treatment of disorders or conditions associated with 5-HT action.
• 5-HT 1 receptors agonists such as 5-HT 1A , 5-HT,,,, 5-HT, c , 5-HTi D , 5-TH 1E or 5-HT
• F agonists for instance 5-HT, A agonists, that can be used for the treatment of disorders or conditions associated with 5-HT action.
• certain compounds of formula (I) also exhibit dopamine D2 receptor antagonist activity.
• certain compounds of formula (I) are highly selective for 5-HT receptors, with little or no affinity for other receptors, such as ⁇ -adrenergic and dopamine D2 receptors, thus reducing the risk of biological side effects.
• certain compounds of formula (I) have greater than 10 fold selectivity for the 5-HT, A receptor with respect to the ⁇ -adrenergic and dopamine D2 receptor.
• certain compounds of formula (I) have greater than 50 fold selectivity for the 5-HT, A receptor with respect to the ⁇ -adrenergic and dopamine D2 receptor.
• certain compounds of formula (I) have greater than 100 fold selectivity for the 5- HT 1A receptor with respect to the ⁇ -adrenergic and dopamine D2 receptor. In a still yet further embodiment, certain compounds of formula (I) have greater than 1000 fold selectivity for the 5-HT, A receptor with respect to the dopamine D2 receptor.
• the term 'C, 6 alkyl' as used herein as a group or a part of the group refers to a linear or branched saturated hydrocarbon group containing from 1 to 6 carbon atoms.
• Examples of such groups include methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert butyl, n-pentyl, isopentyl, neopentyl or hexyl and the like.
• Ci 6 alkoxy' refers to an -0-C 1 6 alkyl group wherein Ci 6 alkyl is as defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy or hexoxy and the like.
• 'C, 8 cycloalkyl' refers to a saturated monocyclic hydrocarbon ring of 3 to 8 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl and the like.
• 'halogen' refers to a fluorine, chlorine, bromine or iodine atom.
• 'aryl' refers to a C 6 12 monocyclic or bicyclic hydrocarbon ring wherein at least one ring is aromatic. Examples of such groups include phenyl, indyl or naphthyl and the like.
• each R 1 independently represents halogen, -CF 3 , -NO 2 , Ci_ 6 alkoxy, -NR 6 COR 7 or
• m represents an integer from 1 to 2, such that when m represents 2, said R 1 groups are not both -NR 6 COR 7 or both -NR 6 SO 2 R 7 or both -NO 2 ;
• R 2 represents C 1-6 alkyl, aryl, or C 3 . 8 cycloalkyl, wherein said aryl may be optionally substituted by one or more (e.g. 1 or 2) R 8 substituents;
• R ⁇ R ⁇ R 5 , R 6 and R 7 independently represent hydrogen or C 1-6 alkyl
• R B represents halogen, -COOH, C 1 6 alkyl, or C 1 6 alkoxy
• T represents a linker selected from -(CH 2 ) n - and C 3-8 cycloalkyl; n represents an integer from O to 4;
• X represents an O or S atom
• Y and Z independently represent a CH or N atom
• W represents a bond, or a linker selected from -C(R 9 MR' 0 )- and C 3 8 cycloalkyl, wherein R 9 and R 10 independently represent hydrogen, C 1 6 alkyl or aryl; or a pharmaceutically acceptable salt, solvate or hydrate thereof.
• R 1 is present at the ortho and/or meta position.
• R 1 represents C 1-6 alkoxy, -NR 6 COR 7 , or - NR 6 SO 2 R 7 .
• R 1 represents methoxy, ethoxy, -CH 3 CONH 2 (ethanamide) or -CH 1 SO 2 NH 2 (methanesulfonamide) .
• R 1 represents -NR 6 COR 7 (e.g. 3-NHCOCH,) .
• R 1 represents - methoxy (e.g. 2-methoxy) .
• R 1 represents - ethanamide (e.g. 3-ethanamide) .
• R 2 represents C,. 6 alkyl (e.g. methyl) or C 8 cycloalkyl (e.g. cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl) .
• R 2 represents aryl (e.g. naphthyl or indyl or phenyl) .
• R 2 represents a phenyl group optionally substituted by one or more (e.g. 1 or 2) R 8 substituents.
• R 8 represents fluorine, chlorine, bromine, -COOH, methyl, propyl (e.g. isopropyl) , butyl (e.g. tert-butyl) , methoxy, or ethoxy.
• R 1 represents C,. 6 alkyl (e.g. methyl, ethyl, or isopropyl) .
• R 3 represents methyl or ethyl.
• R 1 represents methyl.
• R 4 represents hydrogen or methyl. In a further embodiment, R 4 represents hydrogen.
• R 5 represents hydrogen
• -A-B- represents -N-CH 2 -.
• T represents -(CH 2 ) n - (e.g. -(CH 2 )-, -(CH 2 ) 2 - or -(CH 2 ),-) .
• T represents -(CH 2 )-. In a yet further embodiment, T represents a group other than -(CH 2 ) 2 -. In a yet further embodiment, T represents -(CH 2 ) ,-.
• X represents an O atom. In one embodiment, Y and Z both represent -CH-.
• W represents a bond, or a linker selected from -CH 2 -, - CH(CH 3 )-, -CH(CH 2 CH 5 )-, -CH(C 6 H 5 )- and cyclopropyl.
• W represents -CH 2 - and R 2 represents C 3-8 cycloalkyl (e.g.cyclohexyl) .
• m 1
• the compounds are selected from E1-E40 or a pharmaceutically acceptable salt, solvate or hydrate thereof.
• the compounds are selected from ElO, E17, E21 , E37 or E38 or a pharmaceutically acceptable salt, solvate or hydrate thereof.
• the compounds are selected from E40-E43 or a pharmaceutically acceptable salt, solvate or hydrate thereof.
• the compound of formula (I) is the compound of E41 or a pharmaceutically acceptable salt, solvate or hydrate thereof (e.g. TV- [3- (4- ⁇ 2- [4- (Cyclohexylmethyl)-l-methyl-5-oxo-4,5-dihydro-lH-l ,2,4-triazol-3- yl]ethyl ⁇ piperazino)phenyl]acetamide) .
• the subject invention also includes isotopically labelled compounds, which are identical to those recited in formula (I) and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number most commonly found in nature.
• isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, iodine, and chlorine, such as 3 H, 11 C, 14 C, 18 F, 123 I and 125 I. Examples of such incorporation may be for compounds of formula (I) wherein R' represents 18 F or -OCH 2 18 F or R 3 represents -CH 2 18 F.
• Isotopically-labeled compounds of the present invention for example those into which radioactive isotopes such as 3 H, 14 C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e. , 1 H, and carbon-14, i.e. , 14 C, isotopes are particularly preferred for their ease of preparation and detectability.
• 11 C and 8 F isotopes are particularly useful in PET (positron emission tomography)
• 125 I isotopes are particularly useful in SPECT (single photon emission computerized tomography) .
• PET and SPECT are useful in brain imaging.
• substitution with heavier isotopes such as deuterium, i.e. , 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances.
• Isotopically labelled compounds of formula (I) and following of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non- isotopically labelled reagent.
• L 1 COR 7 a compound of formula L 1 COR 7 , wherein L' represents a suitable leaving group such as chlorine, and R 2 , R", R 5 ,
• R 6 , R 7 , -A-B-, T, X, Y, Z and W are as defined for formula (I) ; and optionally thereafter
• Step (d) deprotection of a protected derivative of formula (I) .
• Step (a) typically comprises treatment of a compound of formula (II) with a strong alkali (e.g. 2M NaOH) .
• a strong alkali e.g. 2M NaOH
• Step (b) typically comprises acylation of the amine of a compound of formula (III) to form an amide, e.g. using an acid halide, e.g. chlorine, in the presence of pyrimidine.
• an acid halide e.g. chlorine
• Step (c) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis, amide bond formation or transition metal mediated coupling reactions.
• transition metal mediated coupling reactions useful as interconversion procedures include the following: Palladium catalysed coupling reactions between organic electrophiles, such as aryl halides, and organometallic reagents, for example boronic acids (Suzuki cross-coupling reactions) ; Palladium catalysed amination and amidation reactions between organic electrophiles, such as aryl halides, and nucleophiles, such as amines and amides; Copper catalysed amidation reactions between organic electrophiles (such as aryl halides) and nucleophiles such as amides; and Copper mediated coupling reactions between phenols and boronic acids.
• R 1 represents hydrogen
• R 3 represents Ci 6 alkyl
• an alkylating agent such as iodomethane
• a solvent e.g. acetonitrile
• a base e.g. PS- BEMP
• step (d) examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991) .
• Suitable amine protecting groups include sulfonyl (e.g. tosyl) , acyl (e.g. acetyl, 2' ,2 ' ,2' -trichloroethoxycarbonyl, benzyloxycarbonyl or t- butoxycarbonyl) and arylalkyl (e.g. benzyl) , which may be removed by hydrolysis (e.g.
• amine protecting groups include trifluoroacetyl (-COCF 3 ) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker) , which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid.
• compounds of formula (II) may be prepared in accordance with the following Scheme 1 , wherein R 2 , R 4 , R 5 , -A-B-, T, X, Y, Z, W and m as defined for formula (I) :
• compounds of formula (III) may be prepared in accordance with the following Scheme 2, wherein R 2 , R 4 , R 5 , -A-B-, T, X, Y, Z and W are as defined for formula (I) :
• the compounds according to the invention may be used in therapy, and this is also an embodiment of the invention.
• the compounds may be used to treat or prevent a variety of disorders or conditions associated with 5-HT action.
• a “disorder or condition associated with 5-HT action” refers to conditions characterised by 5-HT excess or absence, e.g. serotonergic hypofunction or hyperfunction, such as those described in WO 2004/069794, the conditions of which are incorporated herein by reference.
• the compounds of the invention are used to treat diseases, disorders or conditions, including, but not limited to, eating disorders, schizophrenia, neuralgia, and addiction disorders; obsessive compulsive disorders, panic disorders, sexual dysfunctions caused by the central nervous system and disturbances in sleep and the absorption of food, alcoholism, pain, memory deficits, unipolar depression, dysthymia, bipolar depression, treatment-resistant depression, depression in the medically ill, panic disorder, obsessive-compulsive disorder, eating disorders, social phobia, premenstrual dysphoric disorder, mood disorders, such as depression or more particularly depressive disorders, for example, single episodic or recurrent major depressive disorders and dysthymic disorders, or bipolar disorders, for example, bipolar I disorder, bipolar II disorder and cyclothymic disorder; anxiety disorders, such as panic disorder with or without agoraphobia, agoraphobia without history of panic disorder, specific phobias, e.
• diseases, disorders or conditions including, but not limited to, eating disorders, schizophrenia, neural
• Parkinson's disease and other extra-pyramidal movement disorders such as medication-induced movement disorders, for example, neuroleptic-induced parkinsonism, neuroleptic malignant syndrome, neuroleptic- induced acute dystonia, neuroleptic-induced acute akathisia, neurol
• conditions characterized by serotonin excess or absence, do not include depression.
• the compounds of the invention may also be used in the treatment of obesity and provide a neuroprotective effect against the above mentioned neurodegenerative disorders.
• the compounds of the invention may further be useful as analgesics in the treatment of pain disorders.
• compounds of the invention may be used for the treatment of vasodilation, smooth muscle contraction, bronchoconstriction, brain disorders such as vascular disorders, e. g, blood flow disorders caused by vasodilation and vasospastic diseases such as angina, vascular headache, migraine and Reynaud's disease; and neuropathological disorders including Parkinson's disease and Alzheimer's disease; modulation of the cardiovascular system; prophylaxis and control of the effects of occurrences of cerebral infarct (Apoplexia cerebri) such as stroke or cerebral ischemia; and for the control of disorders of the intestinal tract which are characterized by disturbances of the serotoninergic system and also by disturbances of the carbohydrate metabolism.
• vascular disorders e. g, blood flow disorders caused by vasodilation and vasospastic diseases such as angina, vascular headache, migraine and Reynaud's disease
• neuropathological disorders including Parkinson's disease and Alzheimer's disease
• modulation of the cardiovascular system prophy
• the compounds may also be useful in treating a variety of other conditions including stress-related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; and pain or nociception attributable to or associated with any of the foregoing conditions, especially pain transmission in migraine.
• the compounds are useful in the treatment of cognitive disorders, including schizophrenia, Alzheimer's disease and dementia.
• the invention thus provides a method for treating or preventing these diseases or states, the method comprising administering to a patient in need thereof a therapeutically effective amount of the compound of formula (I) without the proviso according to the invention.
• treatment means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder.
• the term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications.
• the patient to be treated is preferably a mammal, in particular a human being, but it may also include animals, such as dogs, cats, cows, sheep and pigs.
• the compounds as described hereinbefore are used to treat or prevent anxiety, more specifically generalised anxiety disorder.
• the compound of formula (I) without the proviso is used to treat or prevent depression.
• the compound of formula (I) without the proviso is used to treat or prevent panic disorder.
• the compound of formula (I) without the proviso is used to treat or prevent attention deficit disorder.
• the compound of formula (I) without the proviso is used to treat or prevent substance-related disorder.
• the compound of formula (I) without the proviso is used to treat or prevent a vascular disorder.
• a use of the compounds of formula (I) without the proviso as hereinbefore defined in the manufacture of a medicament for the treatment or prevention of the diseases, disorders or conditions as hereinbefore described in a further embodiment, there is provided a pharmaceutical composition comprising a compound of formula (I) without the proviso as hereinbefore defined for use in the treatment of the diseases, disorders or conditions as hereinbefore described.
• combination therapies may include administration of a compound according to the present invention in combination with a medicament useful for treating anxiety and/or depression such as those disclosed in WO 2004/002858, herein incorporated by reference.
• the compounds may be used with other 5-HT agonist/antagonists, and/or selective serotonin reuptake inhibitors (SSRIs) and/or serotonin noradrenaline reuptake inhibitors (SNRIs) .
• SSRIs selective serotonin reuptake inhibitors
• SNRIs serotonin noradrenaline reuptake inhibitors
• Such combination therapy may also include administration of a compound according to the present invention together with anti-migraine agents, such as those disclosed in WO 2004/002858, herein incorporated by reference.
• Such combination therapy may also include administration of a compound according to the present invention together with anti-psychotic agents, such as those disclosed in WO 2004/002858, herein incorporated by reference.
• combination treatment may be carried out in any way as deemed necessary or convenient by the person skilled in the art and for the purpose of this specification, no limitations with regard to the order, amount, repetition or relative amount of the compounds to be used in combination is contemplated.
• Another purpose is to provide a pharmaceutical composition comprising the compounds of the invention.
• the compounds of the invention may be generally utilised as the free substance or as a pharmaceutically acceptable salt thereof.
• salts are intended to indicate salts which are not harmful to the patient.
• Such salts include pharmaceutically acceptable acid addition salts, pharmaceutically acceptable metal salts, ammonium and alkylated ammonium salts.
• Acid addition salts include salts of inorganic acids as well as organic acids. Representative examples of suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, nitric acids and the like.
• suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenesulfonic acids and the like.
• compositions include the pharmaceutically acceptable salts listed in J. Pharm. Sci. 1977, 66, 2, which is incorporated herein by reference.
• metal salts include lithium, sodium, potassium, magnesium salts and the like.
• ammonium and alkylated ammonium salts include ammonium, methylammonium, dimethylammonium, trimethylammonium, ethylammonium, hydroxyethylammonium, diethylammonium, butylammonium, tetramethylammonium salts and the like.
• compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 lh Edition, Gennaro, Ed. , Mack Publishing Co. , Easton, PA, 1995.
• Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
• solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc, gelatine, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
• liquid carriers are syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water.
• the compounds of the invention may form solvates with water or common organic solvents. Such solvates are also encompassed within the scope of the present invention.
• composition comprising a compound of formula (I) without the proviso to:
• the composition may further comprise a buffer system, preservative(s) , tonicity agent(s) , chelating agent(s) , stabilizers and surfactants, which is well known to the skilled person. For convenience reference is made to Remington: The Science and Practice of Pharmacy, 20th edition, 2000.
• the composition may also further comprise one or more therapeutic agents active against the same disease state.
• Methods to produce controlled release systems useful for compositions of the current invention include, but are not limited to, crystallization, condensation, co-crystallization, precipitation, co-precipitation, emulsification, dispersion, high pressure homogenisation, en-capsulation, spray drying, microencapsulating, coacervation, phase separation, solvent evaporation to produce microspheres, extrusion and supercritical fluid processes.
• General reference is made to Handbook of Pharmaceutical Controlled Release (Wise, D. L. , ed. Marcel Dekker, New York, 2000) and Drug and the Pharmaceutical Sciences vol. 99: Protein Composition and Delivery (MacNally, E.J. , ed. Marcel Dekker, New York, 2000) .
• Administration of pharmaceutical compositions according to the invention may be through several routes of administration, for example, oral, rectal, nasal, pulmonary, topical (including buccal and sublingual) , transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route.
• routes of administration for example, oral, rectal, nasal, pulmonary, topical (including buccal and sublingual) , transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route.
• routes of administration for example, oral, rectal, nasal, pulmonary, topical (including buccal and sublingual) , transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) route.
• topical applications For topical use, sprays, creams, ointments, jellies, gels, inhalants, dermal patches, implants, solutions of suspensions, etc. , containing the compounds of the present invention are contemplated.
• topical applications shall include mouth washes and gargles.
• compositions for oral administration include solid dosage forms such as hard or soft capsules, tablets, troches, dragees, pills, lozenges, powders and granules and liquid dosage forms for oral administration include solutions, emulsions, aqueous or oily suspensions, syrups and elixirs, each containing a predetermined amount of the active ingredient, and which may include a suitable excipient.
• compositions intended for oral use may be prepared according to any known method, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents, and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
• Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically-acceptable excipients which are suitable for the manufacture of tablets.
• excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
• inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate
• granulating and disintegrating agents for example corn starch or alginic acid
• binding agents for example, starch, gelatin or acacia
• lubricating agents for example magnesium stearate, stearic acid or talc.
• the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
• a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
• Formulations for oral use may also be presented as hard gelatine capsules where the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatine capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
• an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
• an oil medium for example peanut oil, liquid paraffin, or olive oil.
• Aqueous suspensions may contain the active compounds in admixture with excipients suitable for the manufacture of aqueous suspensions.
• excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide such as lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example, heptadecaethyl-eneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene
• Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as a liquid paraffin.
• the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
• Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
• Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active compound in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives .
• Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavouring, and colouring agents may also be present.
• the pharmaceutical compositions of the present invention may also be in the form of oil-in- water emulsions.
• the oily phase may be a vegetable oil, for example, olive oil or arachis oil, or a mineral oil, for example a liquid paraffin, or a mixture thereof.
• Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
• the emulsions may also contain sweetening and flavouring agents.
• Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
• the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents described above.
• the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
• Suitable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
• sterile, fixed oils are conveniently employed as a solvent or suspending medium.
• any bland fixed oil may be employed using synthetic mono- or diglycerides.
• fatty acids such as oleic acid find use in the preparation of injectables.
• Parenteral administration may be performed by subcutaneous, intramuscular, intraperitoneal or intravenous injection by means of a syringe, optionally a pen- like syringe.
• parenteral administration can be performed by means of an infusion pump.
• a further option is a composition which may be a solution or suspension for the administration of the prolactin receptor antagonist in the form of a nasal or pulmonal spray.
• the pharmaceutical compositions containing the compound of the invention can also be adapted to transdermal administration, e.g. by needle-free injection or from a patch, optionally an iontophoretic patch, or transmucosal, e.g. buccal, administration.
• compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
• aqueous composition is defined as a composition comprising at least 50 % w/w water.
• aqueous solution is defined as a solution comprising at least 50 %w/w water
• aqueous suspension is defined as a suspension comprising at least 50 %w/w water.
• aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
• the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
• the sterile aqueous media employed are all readily available by standard techniques known to those skilled in the art. Depot injectable formulations are also contemplated as being within the scope of the present invention.
• the compounds of the invention or composition thereof When used in combination with a second therapeutic agent active against the same disease state, they may conveniently be administered alone or in combination, in either single or multiple doses, sequentially or simultaneously, by the same route of administration, or by a different route.
• the compounds of the invention, or compositions thereof, will generally be used in an amount effective to achieve the intended result, for example in an amount effective to treat or prevent the particular disease being treated.
• the compound(s) may be administered therapeutically to achieve therapeutic benefit.
• therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated and/or eradication or amelioration of one or more of the systems associated with the underlying disorder.
• Therapeutic benefit also includes halting or slowing the progression of the disease, regardless of whether improvement is realised.
• the exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art. Determination of the effective dosage is well within the capabilities of those skilled in the art.
• each compound of the invention When a compound of the invention or a pharmaceutically acceptable salt, solvate or prodrug thereof is used in combination with a second therapeutic agent active against the same disease state the dose of each compound may differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.
• El may be prepared in an analogous manner to E2, ElO and E17.
• EXAMPLE 2 5- ⁇ 2-[4-(2-Methoxyphenyl)piperazino]ethyl ⁇ -4-phenyl-2,4- dihydro-3//-l,2,4-triazol-3-one (E2)
• E3-E9 may be prepared in an analogous manner to E2, ElO and E17.
• EXAMPLE 5 4-(4-Methoxy-phenyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l- yl]-ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E5)
• EXAMPLE 6 4-(4-Chloro-phenyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l- yl]-ethyl ⁇ -2,4-dihydro-[l ,2,4]triazol-3-one (E6)
• EXAMPLE 7 4-Cyclopentyl-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l-yl]- ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E7) ⁇ ---.# , u u ⁇ w Q O
• EXAMPLE 8 4-Cyclohexyl-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l-yl]- ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E8)
• EXAMPLES 11-16 E11-E16 may be prepared in an analogous manner to E2, ElO and E17.
• EXAMPLE 11 5- ⁇ 2-[4-(2-Methoxy-phenyl)-piperazin-l-yl]-ethyl ⁇ -4- naphthalen-2-yl-2,4-dihydro-[l,2,4]triazol-3-one (Ell)
• EXAMPLE 12 5- ⁇ 2-[4-(2-Methoxy-phenyl)-piperazin-l-yl]-ethyl ⁇ -4-p-tolyl- 2,4-dihydro-[l,2,4]triazol-3-one (E12)
• EXAMPLE 13 4-Benzyl-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l-yl]-ethyl ⁇ - 2,4-dihydro-[l,2,4]triazol-3-one (E13)
• EXAMPLE 14 4-(4-Isopropyl-phenyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin- l-yl]-ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E14)
• EXAMPLE 15 4-(4-tert-Butyl-phenyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin- l-yl]-ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E15)
• EXAMPLE 17 4-(Cyclohexylmethyl)-5- ⁇ 2-[4-(2- methoxyphenyl)piperazino]ethyI ⁇ -2,4-dihydro-3//-l,2,4-triazol-3-one (E17)
• E18-E33 may be prepared in an analogous manner to E2, ElO and E17.
• EXAMPLE 18 5- ⁇ 2-[4-(2-Methoxy-phenyl)-piperazin-l-yl]-ethyl ⁇ -4-(l- phenyl-ethyl)-2,4-dihydro-[l,2,4]triazol-3-one (E18)
• EXAMPLE 20 4-(4-Chloro-benzyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l- yl]-ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E20)
• EXAMPLE 23 5- ⁇ 2-[4-(2-Methoxy-phenyl)-piperazin-l-yl]-ethyl ⁇ -4-(2- phenyl-cyclopropyl)-2,4-dihydro-[l,2,4]triazol-3-one (E23)
• EXAMPLE 24 5- ⁇ 2-[4-(2-Methoxy-phenyI)-piperazin-l-yl]-ethyl ⁇ -4-(2- methyl-benzyl)-2,4-dihydro-[l,2,4]triazol-3-one (E24)
• EXAMPLE 25 4-(2,4-Dichloro-benzyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)- piperazin-l-yl]-ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E25)
• EXAMPLE 26 4-(3-Fluoro-benzyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l- yl]-ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E26)
• EXAMPLE 27 5- ⁇ 2-[4-(2-Methoxy-phenyl)-piperazin-l-yl]-ethyl ⁇ -4-(4- methyl-benzyl)-2,4-dihydro-[l,2,4]triazol-3-one (E27)
• EXAMPLE 28 4-Benzhydryl-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l-yl]- ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E28)
• EXAMPLE 29 4-Indan-l-yl-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l-yl]- ethyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E29)
• EXAMPLE 30 4-(2-Fluoro-benzyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l- yl]-ethyl ⁇ -2,4-dihydro-[l ,2,4]triazol-3-one (E30)
• EXAMPLE 32 4-(2-Chloro-benzyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l- yl]-ethyl ⁇ -2,4-dihydro-[l ,2,4]triazol-3-one (E32)
• EXAMPLE 33 4-(3,4-Dichloro-phenyl)-5- ⁇ 2-[4-(2-methoxy-phenyl)- piperazin-l-yl]-ethyl ⁇ -2,4-dihydro-[l ,2,4]triazol-3-one (E33)
• EXAMPLES 34-36 E34-E36 may be prepared in an analogous manner to E37.
• EXAMPLE 35 4-(3- ⁇ 2-[4-(2-Methoxy-phenyl)-piperazin-l-yl]-propyl ⁇ -5-oxo- l,5-dihydro-[l,2,4]triazol-4-yl)-benzoic acid (E35)
• EXAMPLE 36 4-Cyclohexylmethyl-5- ⁇ 2-[4-(2-methoxy-phenyl)-piperazin-l- yl]-propyl ⁇ -2,4-dihydro-[l,2,4]triazol-3-one (E36)
• EXAMPLE 37 4-(Cyclohexylmethyl)-5- ⁇ 2-[4-(2-methoxyphenyl)piperazin-l- yl]propyl ⁇ -2-methyl-2,4-dihydro-3i c /-l,2,4-triazol-3-one (E37)
• EXAMPLE 38 N-[3-(4- ⁇ 2-[4-(Cyclohexylmethyl)-5-oxo-4,5-dihydro-li/- l ,2,4-triazol-3-yl]ethyl ⁇ piperazin-l-yl)phenyl]acetamide (E38)
• EXAMPLES 39-40 E39-E40 may be prepared in an analogous manner to E38.
• EXAMPLE 40 N-(3- ⁇ 4-[4-(4-Cyclohexylmethyl-5-oxo-4,5-dihydro-lH- [l,2,4]triazol-3-yl)-butyl]-piperazin-l-yl ⁇ -phenyl)-acetamide (E40)
• EXAMPLE 41 yV-[3-(4- ⁇ 2-[4-(Cyclohexylmethyl)-l-methyl-5-oxo-4,5- dihydro-l//-l,2,4-triazol-3-yl]ethyl ⁇ piperazino)phenyl]acetamide (E41)
• EXAMPLE 42 4-(Cyclohexylmethyl)-5- ⁇ 2-[4-(2-methoxyphenyl) piperazino]ethyl ⁇ -2-methyl-2,4-dihydro-3//-l,2,4-triazol-3-one (E42)
• EXAMPLE 43 4-(Cyclohexylmethyl)-2-ethyl-5- ⁇ 2-[4-(2-methoxyphenyl) piperazino]ethyl ⁇ -2,4-dihydro-3//-l,2,4-triazol-3-one (E43)
• a Receptor Assay The determination of binding of the ligand with 5HT 1A receptor was carried out according to the procedures described in Martin GR and Humphrey PPA. Neuropharmacol. 33 : 261-273.
• radiolabeled 1.5 nM [3H]8-OH-DPAT was incubated for 60 minutes at 25°C with 5HT 1A transfected human recombinant CHO cell membranes in 50 mM Tris-HCl, pH7.4, 0.1% Ascorbic acid, 1OmM MgSO4.7H2O and 0.5mM EDTA and increasing concentrations of test compound.
• the non-specific ligand used was 1OmM Metergoline. Significance criteria were 50% of max stimulation or inhibition.
• ⁇ l-Adrenergic Receptor Assay The determination of binding of the ligand with ⁇ l -adrenergic receptor was carried out according to the procedures described in Greengrass P and Bremner R. Eur. J. Pharmacol. 1979, 55: 323-326.
• radiolabeled 0.16 nM [3H]Spiperone was incubated for 120 minutes at 25oC with D2L transfected human recombinant CHO cells in 50 mM Tris-HCl, pH7.4, 15OmM NaCl, 1.4mM Ascorbic acid, 0.001% BSA and increasing concentrations of test compound.
• the compounds of Examples 37, 38 and 39 were additionally tested in the ⁇ l- adrenergic receptor assay and demonstrated an affinity for 5HT 1A that is more than fifty times greater than their affinity for ⁇ l-adrenergic receptors.
• the compounds of Examples 37 and 38 were also tested in the Dopamine D2 receptor assay and demonstrated an affinity for 5HT, A that is more than fifty times greater than their affinity for dopamine D2 receptors.
• Example 41 was also tested in the Dopamine D2 receptor assay and demonstrated an affinity for 5HT 1 A that is more than a thousand times greater than its affinity for dopamine D2 receptors.
• GTP ⁇ S binding for 5HT1A was determined according to the procedures of Adlersberg et al. J Neurosci. Res. 2000, 61(6) : 674-685. Compounds were incubated for 30 minutes at 30°C in 2OmM HEPES, pH7.4, 10OmM NaCl,
• the compounds of Examples 13, 17 and 26 demonstrated half lives of at least 1 hour in both rat and human liver microsomes.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Psychiatry (AREA)
• Pain & Pain Management (AREA)
• Addiction (AREA)
• Reproductive Health (AREA)
• Epidemiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Psychology (AREA)
• Gynecology & Obstetrics (AREA)
• Pregnancy & Childbirth (AREA)
• Rheumatology (AREA)
• Endocrinology (AREA)
• Cardiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Priority Applications (5)

Applications Claiming Priority (4)

Publications (2)

Family

ID=39767579

Family Applications (1)

Country Status (7)

Cited By (3)

Families Citing this family (4)

Citations (9)

Family Cites Families (1)

• 2008
  • 2008-08-06 CN CN2008801021328A patent/CN101827828B/zh not_active Expired - Fee Related
  • 2008-08-06 GB GB0814351A patent/GB2454290B/en not_active Expired - Fee Related
  • 2008-08-06 JP JP2010519520A patent/JP5358571B2/ja not_active Expired - Fee Related
  • 2008-08-06 CA CA2694621A patent/CA2694621C/en not_active Expired - Fee Related
  • 2008-08-06 WO PCT/GB2008/002669 patent/WO2009019472A1/en not_active Ceased
  • 2008-08-06 US US12/670,829 patent/US8222254B2/en not_active Expired - Fee Related
  • 2008-08-06 EP EP08776140.9A patent/EP2183227B1/en not_active Not-in-force

Patent Citations (9)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events